Related Experiment Video
Updated: May 17, 2026
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
The impact of ethnicity on hepatitis C virus treatment decisions and outcomes
Mauricio Lisker-Melman1, José L Walewski
1Hepatology Program, Division of Gastroenterology, Washington University School of Medicine, St. Louis, MO 63110-1010, USA. mlisker@im.wustl.edu
Insights
Hepatitis C virus (HCV) infection affects millions, with treatment success varying by ethnicity. Understanding genetic and socioeconomic factors is key to improving outcomes for all patients.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Hepatitis C virus (HCV) infection is a significant global health issue, with millions affected in the US.
- Current therapies, like pegylated-interferon/ribavirin, show limited efficacy (around 50% sustained virologic response in G1 patients).
- Ethnic and racial variations in treatment response are observed but poorly understood, with historical underrepresentation of these groups in clinical trials.
Purpose of the Study:
- To investigate genetic variations influencing HCV clearance and treatment outcomes in diverse ethnic populations.
- To explore the role of socioeconomic and biological factors in HCV infection, progression, and treatment disparities.
- To identify host factors contributing to treatment outcome variations.
Main Methods:
- Analysis of genetic variations in biological pathways relevant to HCV infection.
- Review of clinical trial data examining treatment responses across different ethnic groups.
- Assessment of socioeconomic and biological determinants of disease progression and treatment success.
Main Results:
- Significant variations in treatment response rates have been reported across different ethnic and racial groups.
- Genetic variations in key biological pathways are being investigated for their role in differential HCV clearance.
- Socioeconomic factors and host biology significantly impact HCV infection, disease progression, and treatment outcomes in minority populations.
Conclusions:
- Addressing ethnic and racial disparities in HCV treatment requires a deeper understanding of host factors.
- Novel direct-acting antiviral drugs are shifting treatment focus away from the innate immune response.
- Optimized treatment strategies incorporating improved healthcare access, new antivirals, and personalized host factor analysis are needed for better patient outcomes.
Abstract:
Hepatitis C virus infection is a major public health concern. Approximately 4 million people are reported to be infected with the virus in the United States, and the annual death rate due to HCV-associated decompensated liver failure or hepatocellular carcinoma is estimated to be approximately 18,000 within the next decade. Therapeutic success, as measured by a sustained virologic response, is approximately 50 % in G1 patients with pegylated-interferon/ribavirin-based therapies. Independent studies have reported significant variation in response rates depending on the ethnicity or race of the patient, though the underlying reasons are not well understood. Historically, ethnic populations have been underrepresented in most large clinical trials of HCV therapies, even though these populations have disproportionately high rates of HCV infection. Recent clinical trials have investigated genetic variations in key biological pathways that may underlie the mechanisms responsible for the different rates of HCV clearance and treatment outcomes in ethnic populations treated with pegylated-interferon/ribavirin. However, as novel direct-acting antiviral drugs are added to, and eventually replace, existing treatment regimens, the role of the innate immune response in determining treatment outcomes will diminish. Socioeconomic and biological factors can impact rates of HCV infection, disease progression, and treatment outcomes in minority populations. Improved access to health care, novel antiviral treatments, and a better understanding of the host factors that contribute to disparities in treatment outcomes are expected to result in optimized treatment paradigms that directly target the virus, leading to improved outcomes for all patients.
Related Concept Videos
01:25Hepatitis
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
01:28Viral Hepatitis I: Introduction